Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer | BMC Cancer | Full Text

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer | BMC Cancer | Full Text

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer.

Authors:Thomas Decker, Ulrike Söling, Antje Hahn, Christoph Maintz, Christian Martin Kurbacher, Ursula Vehling-Kaiser, Dagmar Sent, Peter Klare, Volker Hagen, Marco Chiabudini, Julia Falkenstein, Martin Indorf, Eva Runkel and Karin Potthoff

Citation:BMC Cancer 2020 20:286

Content type:Research article

Published on: 6 April 2020

• ViewFull Text
 
• ViewPDF